Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence P Carter

Showing results (21-30 of 45) with videos related to

Pageof 5
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|March 19, 2005
Discriminative stimulus effects of gamma-hydroxybutyrate (GHB) in rats discriminating GHB from baclofen and diazepamWouter Koek, Lawrence P Carter, R J Lamb, et al.
Molecular Genetics and Metabolism|January 13, 2006
Succinate semialdehyde dehydrogenase deficiency does not down-regulate gamma-hydroxybutyric acid binding sites in the mouse brainAshok K Mehta, Georgianna G Gould, Maneesh Gupta, et al.
Journal of Psychopharmacology (Oxford, England)|October 2, 2018
A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitorLawrence P Carter, Jack E Henningfield, Y Grace Wang, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 16, 2007
Relative abuse liability of indiplon and triazolam in humans: a comparison of psychomotor, subjective, and cognitive effectsLawrence P Carter, Roland R Griffiths, Patricia E Suess, et al.
Psychopharmacology|April 25, 2012
High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogensChad J Reissig, Lawrence P Carter, Matthew W Johnson, et al.
Drug and Alcohol Dependence|September 20, 2012
Acute cognitive effects of high doses of dextromethorphan relative to triazolam in humansLawrence P Carter, Chad J Reissig, Matthew W Johnson, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 5, 2009
Abuse liability assessment of tobacco products including potential reduced exposure productsLawrence P Carter, Maxine L Stitzer, Jack E Henningfield, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 28, 2003
The role of GABAB receptors in the discriminative stimulus effects of gamma-hydroxybutyrate in rats: time course and antagonism studiesLawrence P Carter, Lauren R Flores, Huifang Wu, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 13, 2018
Characterization of the Neurochemical and Behavioral Effects of Solriamfetol (JZP-110), a Selective Dopamine and Norepinephrine Reuptake InhibitorMichelle G Baladi, Michael J Forster, Michael B Gatch, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 22, 2003
Effects of gamma-hydroxybutyrate (GHB) on schedule-controlled responding in rats: role of GHB and GABAB receptorsLawrence P Carter, Huifang Wu, Weibin Chen, et al.
Pageof 5

Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
The Journal of Pharmacology and Experimental Therapeutics|March 19, 2005
Discriminative stimulus effects of gamma-hydroxybutyrate (GHB) in rats discriminating GHB from baclofen and diazepamWouter Koek, Lawrence P Carter, R J Lamb, et al.
Molecular Genetics and Metabolism|January 13, 2006
Succinate semialdehyde dehydrogenase deficiency does not down-regulate gamma-hydroxybutyric acid binding sites in the mouse brainAshok K Mehta, Georgianna G Gould, Maneesh Gupta, et al.
Journal of Psychopharmacology (Oxford, England)|October 2, 2018
A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitorLawrence P Carter, Jack E Henningfield, Y Grace Wang, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 16, 2007
Relative abuse liability of indiplon and triazolam in humans: a comparison of psychomotor, subjective, and cognitive effectsLawrence P Carter, Roland R Griffiths, Patricia E Suess, et al.
Psychopharmacology|April 25, 2012
High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogensChad J Reissig, Lawrence P Carter, Matthew W Johnson, et al.
Drug and Alcohol Dependence|September 20, 2012
Acute cognitive effects of high doses of dextromethorphan relative to triazolam in humansLawrence P Carter, Chad J Reissig, Matthew W Johnson, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 5, 2009
Abuse liability assessment of tobacco products including potential reduced exposure productsLawrence P Carter, Maxine L Stitzer, Jack E Henningfield, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 28, 2003
The role of GABAB receptors in the discriminative stimulus effects of gamma-hydroxybutyrate in rats: time course and antagonism studiesLawrence P Carter, Lauren R Flores, Huifang Wu, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 13, 2018
Characterization of the Neurochemical and Behavioral Effects of Solriamfetol (JZP-110), a Selective Dopamine and Norepinephrine Reuptake InhibitorMichelle G Baladi, Michael J Forster, Michael B Gatch, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 22, 2003
Effects of gamma-hydroxybutyrate (GHB) on schedule-controlled responding in rats: role of GHB and GABAB receptorsLawrence P Carter, Huifang Wu, Weibin Chen, et al.
Pageof 5